Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis.

Trial Profile

A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PsA-I
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 Feb 2022 Results of post hoc analysis assessing implementation of OMERACT Psoriatic Arthritis MRI Scoring System in this study published in the Rheumatology
    • 05 Oct 2021 According to Eudra the trial has been completed in France.
    • 05 Jun 2021 Results of an analysis retrospectively assessing utilization of the Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) presented at the 22nd Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top